| Fri, Dec 18, 2009 | | • | 2009: The Year Pharma Learned to Love Itself
at Motley Fool (Fri, Dec 18)
| | • | 3 Reasons to Sell Dendreon Today
at Motley Fool (Fri, Dec 18)
| | • | 3 Reasons to Buy Dendreon Today
at Motley Fool (Fri, Dec 18)
| | • | Celgene's Boon; Genzyme Takes Flack; A Genomic Vision
at Forbes.com (Fri, Dec 18)
| | • | Eli Lilly CFO takes on global service duties
AP (Fri, Dec 18)
| | • | UPDATE - Lilly wins British drug patent case vs Dr Reddy's
at Reuters (Fri, Dec 18)
| | • | Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President
PR Newswire (Fri, Dec 18)
| | Thu, Dec 17, 2009 | | • | TradingMarkets 7 Stocks You Need to Know for Friday
TradingMarkets.com (Thu, Dec 17)
| | • | This Acquisition Hears, Smells, and Tastes Soooo Good
at Motley Fool (Thu, Dec 17)
| | • | Lilly to Benefit from OSI Rejection
at Seeking Alpha (Thu, Dec 17)
| | • | This Just In: Upgrades and Downgrades
at Motley Fool (Thu, Dec 17)
| | • | Why Big Pharmas 2010 Looks Challenging
at Minyanville.com (Thu, Dec 17)
| | • | FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
PR Newswire (Thu, Dec 17)
| | • | UPDATE - Roche, Ipsen diabetes drug meets goals in studies
at Reuters (Thu, Dec 17)
| | • | The Super and Stupor in Recent Dividend News
at Seeking Alpha (Thu, Dec 17)
| | Wed, Dec 16, 2009 | | • | UK's NICE rejects maintenance use of Lilly drug
at Reuters (Wed, Dec 16)
| | • | Amylin Impresses in Head-to-Head
Zacks.com (Wed, Dec 16)
| | • | UPDATE - Silence seeks louder voice in RNAi with Intradigm
at Reuters (Wed, Dec 16)
| | • | 4-Star Stocks Poised to Pop: Eli Lilly
at Motley Fool (Wed, Dec 16)
| | • | Coverage initiated on Eli Lilly by UBS
Briefing.com (Wed, Dec 16)
|
Add LLY News to My Yahoo!:
 
| |
|
0.20% Nasdaq 
Headlines
